Breaking News Instant updates and real-time market news.

MOR

MorphoSys

$29.63

0.75 (2.60%)

, JNJ

Johnson & Johnson

$128.23

1.16 (0.91%)

08:47
01/28/19
01/28
08:47
01/28/19
08:47

MorphoSys announces asserted claims of three patents ruled invalid

MorphoSys (MOR) announces that it was informed today that in its lawsuit against Janssen Biotech (JNJ) and Genmab A/S (GMXAY), the United States District Court of Delaware, based on a hearing held November 27, 2018, has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746; 9,200,061 and 9,758,590 are invalid. The Court thus granted a motion for summary judgement of invalidity filed by Janssen Biotech and Genmab against the three patents held by MorphoSys. As a result of this decision, the jury trial scheduled for February 2019 to consider defendants' alleged infringement and the validity of the MorphoSys patents will now not take place. "MorphoSys's management is disappointed with the decision and is considering all of its options. The company has the right to appeal this judgement to the Federal Circuit," the company stated.

MOR

MorphoSys

$29.63

0.75 (2.60%)

JNJ

Johnson & Johnson

$128.23

1.16 (0.91%)

GMXAY

Genmab ticker changed to GMAB

$0.00

(0.00%)

  • 18

    Feb

  • 25

    Feb

  • 06

    Mar

MOR MorphoSys
$29.63

0.75 (2.60%)

12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
MorphoSys upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Gunnar Romer upgraded MorphoSys (MOR) to Buy and raised his price target for the shares to EUR 130 from EUR 120. The company's 115 antibody drug candidates offer "best-in-class risk diversification and value-creation potential," Romer tells investors in a research note. Further, he believes Tremfya, which is partnered with Johnson & Johnson (J&J), is on its way to becoming a multi-billion blockbuster.
12/06/18
PIPR
12/06/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys share setup remains positive, says Piper Jaffray
Updates at MorphoSys AG's investor day were incremental, though future development plans for MOR208 in front-line diffuse large B-cell lymphoma were outlined, Piper Jaffray analyst Danielle Brill tells investors in a research note. While the analyst hoped pivotal development in the front-line setting would begin sooner than mid-2020, she appreciates "de-risking" the program by running a small study first. She continues to think the setup for MorphoSys is positive and keeps an Overweight rating on the shares with a $38 price target.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys' MOR208 ASH data 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that MorphoSys presented MOR208 data at ASH, and says she is particularly encouraged that MOR208 efficacy is consistent across of cell-of-origin and in rituximab refractory patients. "It's difficult to poke holes in the data which were deemed remarkable by the lead investigator," she contends. Brill thinks MOR208 has made it onto the radar screens of physicians and has huge potential in DLBCL. Additionally, the analyst thinks the next likely catalyst is an "attractive partnership" for MOR208 development and commercialization outside of the U.S. She reiterated an Overweight rating and $38 price target on the shares.
11/28/18
PIPR
11/28/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys's MOR208 remains key focus for company, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys following her meeting with its CEO Simon Maroney at Piper Jaffray Healthcare Conference. The analyst notes that the company remains focused on the development of MOR208 and believes that the drug could become "cornerstone" of Diffuse Large B-Cell Lymphoma, or DBLCL, therapy, remaining "very bullish" on the name. Brill adds that her survey of doctors treating lymphoma at the conference revealed that 46% would use MOR208 for their DBLCL patients.
JNJ Johnson & Johnson
$128.23

1.16 (0.91%)

01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
01/14/19
WELS
01/14/19
NO CHANGE
Target $152
WELS
Outperform
Johnson & Johnson price target lowered to $152 from $162 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered his price target for Johnson & Johnson to $152 from $162 ahead of quarterly results. The analyst forecasts Q4 sales of $20.1B and EPS of $1.97, versus consensus of $20.2B and $1.95, respectively. For 2019, Biegelsen expects initial guidance to be conservative based on the company's track record, and J&J to continue to target earnings to grow faster than sales. The analyst sees 5%-6% operational EPS growth as "reasonable." He reiterates an Outperform rating on the shares.
01/24/19
BARD
01/24/19
NO CHANGE
Target $155
BARD
Outperform
HCA Healthcare elevated to Fresh Pick at Baird
Baird analyst Matthew Gillmor elevated HCA Healthcare (HCA) to Fresh Pick ahead of its Q4 report. The analyst said recent commentary from UnitedHealth (UNH) and Johnson & Johnson (JNJ) suggest Q4 patient volumes remain solid, which he thinks will translate into EBITDA upside for HCA. Gillmor reiterated his Outperform rating and $155 price target on HCA Healthcare shares.
GMXAY Genmab ticker changed to GMAB
$0.00

(0.00%)

01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Genmab downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Genmab to Neutral with an unchanged price target of FKK 1,150. The analyst believes Darzalex's potential is largely reflected in the shares at current levels.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
Genmab upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Genmab to Buy and raised his price target for the shares to DKK 1,250 from DKK 1,220. The analyst says the shares are "well underpinned" by Darzalex while the company's pipeline is maturing.
10/01/18
HCWC
10/01/18
INITIATION
HCWC
Buy
Genmab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Genmab with a Buy rating and DKK 1,600 price target.
06/20/18
JPMS
06/20/18
UPGRADE
JPMS
Overweight
Genmab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Quigley upgraded Genmab with an increased price target of 1,150 kroner. The market is overly cautious on Darzalex competition and recent pullback in shares offers an attractive entry point, Quigley tells investors in a research note.

TODAY'S FREE FLY STORIES

TNXP

Tonix Pharmaceuticals

$0.45

0.0048 (1.07%)

17:12
10/18/19
10/18
17:12
10/18/19
17:12
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

POAI

Predictive Oncology

$0.44

0.0101 (2.35%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BK

BNY Mellon

$45.34

0.975 (2.20%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
BNY Mellon SVP Harris sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
Breaking Hot Stocks news story on Foamix 

Foamix trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

BAC

Bank of America

$30.37

0.1 (0.33%)

16:35
10/18/19
10/18
16:35
10/18/19
16:35
Hot Stocks
Bank of America's Knox sells 40,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

LGC

Legacy Acquisition Corp

$10.24

0.02 (0.20%)

16:34
10/18/19
10/18
16:34
10/18/19
16:34
Conference/Events
Legacy Acquisition Corp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

16:33
10/18/19
10/18
16:33
10/18/19
16:33
Periodicals
OpenText weighing takeover bid for rival Micro Focus, Bloomberg says »

Open Text (OTEX) is…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

16:30
10/18/19
10/18
16:30
10/18/19
16:30
Options
Preliminary option volume of 21.9M today »

Preliminary option volume…

BA

Boeing

$344.01

-25.12 (-6.81%)

, ORCL

Oracle

$54.55

-0.52 (-0.94%)

16:22
10/18/19
10/18
16:22
10/18/19
16:22
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. earnings have…

BA

Boeing

$344.01

-25.12 (-6.81%)

ORCL

Oracle

$54.55

-0.52 (-0.94%)

KO

Coca-Cola

$54.78

0.98 (1.82%)

AXP

American Express

$116.82

-2.35 (-1.97%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

M

Macy's

$15.11

-0.66 (-4.19%)

LB

L Brands

$16.32

-1.78 (-9.83%)

GPS

Gap

$16.87

-0.71 (-4.04%)

LEVI

Levi Strauss

$17.12

0.07 (0.41%)

DERM

Dermira

$7.17

1.49 (26.23%)

ETFC

E-Trade

$40.82

1.78 (4.56%)

GIL

Gildan Activewear

$26.29

-9.085 (-25.68%)

TEAM

Atlassian

$116.96

-5.47 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 06

    Dec

  • 07

    Dec

EYEG

EyeGate

$3.40

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for October 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$20.36

0.36 (1.80%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Hot Stocks
Glenview Capital discloses 14.7% activist stake in Meritor »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BCBP

BCB Bancorp

$12.91

-0.04 (-0.31%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Earnings
BCB Bancorp reports Q3 EPS 30c, consensus 30c »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/18/19
10/18
16:16
10/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$5.35

0.12 (2.29%)

16:15
10/18/19
10/18
16:15
10/18/19
16:15
Syndicate
Breaking Syndicate news story on Universal Technical »

Universal Technical files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$246.37

2.62 (1.07%)

16:13
10/18/19
10/18
16:13
10/18/19
16:13
Hot Stocks
UnitedHealth's Burke sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:09
10/18/19
10/18
16:09
10/18/19
16:09
Hot Stocks
Foamix announces FDA approval of AMZEEQ topical foam, 4% »

Foamix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees Q3 net sales $325M, consensus $348.82M »

Michael F. Barry,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees FY19 pro forma adjusted EBITDA down 2%-4% »

Quaker Houghton updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.